BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 374 participants.
Also called NCT07628985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 374 participants
- Sponsor
- Carnot Laboratories
- Registry
-
NCT07628985
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Mexico
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07628985. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Intervention (Biological)
- Bofanglutide
- Intervention (Biological)
- Semaglutide
- Lead sponsor
- Carnot Laboratories
Record details
- Record id
cardio:ct-nct07628985- Content hash
3db9bc388f2c9c3d6003a5d0c094c6f4fa606347949d75d50974c16c7d2ebfe3